(lp0
S'Exclusive: Impax Laboratories taps Morgan Stanley for strategic review - sources Reuters - Mar 7, 2017 Generic drugmaker Impax Laboratories Inc  has asked investment bank Morgan Stanley  to help it conduct a strategic review, as it tries to cope with a tougher drug pricing environment, people familiar with the matter said.Impax Laboratories Inc.  Moves Higher on Volume Spike for March 06 - Equities.comWeatherford International, Impax Laboratories, Cytokinetics Upgraded - Schaeffers Research '
p1
aS'Impax to Present at Upcoming Investor Conferences PR Newswire  - Feb 27, 2017 Impax Laboratories, Inc.  is a specialty pharmaceutical company applying its formulation expertise and drug delivery technology to the development of controlled-release and specialty generics in addition to the development of central nervous ...Impax Laboratories, Inc.  Scheduled to Post Earnings on Wednesday - Sports PerspectivesImpax Laboratories, Inc.  Receives An Update From Brokers - The De Soto Edge'
p2
aS'Impax Laboratories, Inc.  Files An 8-K Results of Operations and ... Market Exclusive - Mar 1, 2017 Impax Laboratories, Inc. is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products , as well as the development and marketing of branded products.Impax Laboratories Inc.  Has Dropped To A New Low After Q4 Report - Nasdaq'
p3
aS'Earnings Reaction History: Impax Laboratories, Inc., 50.0% Follow-Through ... Nasdaq - Mar 1, 2017 Impax Laboratories, Inc.  is due to issue its quarterly earnings report in the upcoming extended-hours session.'
p4
aS"Why Analysts put forward these two stocks: Intrexon Corporation , Impax ... The USA Commerce - 20 hours ago Shares of Intrexon Corporation  dropped -8.88% to $20.83. During the trading on 03/14/2017, Company's stock ranged from $20.80 to $22.75."
p5
aS'Impax Laboratories  is Oversold: Can It Recover? March 02, 2017 Zacks.com - Mar 2, 2017 Impax Laboratories, Inc.  has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.'
p6
aS"112 institutional investors are raising stakes in Impax Laboratories, Inc ... Post Analyst - 14 hours ago Impax Laboratories, Inc.  reached 14.84% versus a 1-year low price of $7.75. The stock was last seen -1.66% lower, reaching at $8.9 on Mar. 14, 2017.Impax Laboratories Inc  Lowered to Neutral at Susquehanna Bancshares Inc - BNB Daily Impax Laboratories, Inc.'s  stock price is now at $8.90 while Analysts ... - Hot Stocks Point"
p7
aS'The Impax Laboratories Inc  Downgraded by Susquehanna Bancshares Inc to ... Petro Global News 24 - Mar 14, 2017 Susquehanna Bancshares Inc lowered shares of Impax Laboratories Inc  from a positive rating to a neutral rating in a research report sent to investors on Wednesday morning.Impax Laboratories, Inc.  Broker Price Targets For The Coming Week - Fiscal Standard'
p8
aS'Revenue Approximations Analysis: Tenet Healthcare Corp. , Impax ... StockNewsJournal - Mar 8, 2017 Impax Laboratories, Inc. , at its latest closing price of $9.10, it has a price-to-book ratio of 0.99, compared to an industry average at 4.15.'
p9
aS"How These Drug Makers Stocks are Faring? -- Sanofi, Impax Laboratories, Heron ... PR Newswire  - Mar 14, 2017 Ahead of today's trading session, Stock-Callers.com shifts focus on four major players in the Drug Manufacturers space: Sanofi SA , Impax Laboratories Inc. , Heron Therapeutics Inc. , and GW Pharmaceuticals&nbsp;..."
p10
a.